Completion of Placement and Exercise of Performance Rights
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises that further to the ASX announcement of 15 August 2022, the Company has today completed Tranche 1 of the $8.0 million placement to UK and Australian-based institutions, and sophisticated and professional investors (the “Placement”). The Company has issued 9,117,647 fully paid ordinary shares (“Shares”) at an iss
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Proteomics raises $8m in highly successful Placement
- Proteomics signs binding LOI with Sonic Healthcare USA
- Clinical Utility Study demonstrates PromarkerD test benefits
- Potential breakthrough blood test for endometriosis
- June 2022 Quarterly Activities Report and Appendix 4C
Later from Proteomics International Laboratories
- OxiDx launched to maximise oxidative stress technology
- New Oesophageal Cancer Diagnostic shows strong performance
- Proteomics receives $1.7 million in R&D tax incentive
- Precision diagnostics facility receives $2m funding boost
- September 2022 Quarterly Activities Report and Appendix 4C
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories